Brief: Ose Immunotherapeutics: Veloxis Pharmaceuticals Obtains FDA Fast-Track Designation For VEL-101

Ose Immunotherapeutics SA

17/02/2022 18:22

Feb 17 (Reuters) - OSE Immunotherapeutics SA  OSE.PA :
    * OSE IMMUNOTHERAPEUTICS IS PLEASED TO ANNOUNCE THAT VELOXIS
PHARMACEUTICALS, INC., ITS PARTNER IN TRANSPLANTATION, HAS
OBTAINED FDA FAST-TRACK DESIGNATION FOR CD28 ANTAGONIST
VEL-101/FR104
    * FAST TRACK DESIGNATION IS GRANTED BY FDA TO FACILITATE
DEVELOPMENT AND EXPEDITE REVIEW OF DRUGS THAT TREAT SERIOUS
CONDITIONS AND FILL AN UNMET MEDICAL NEED
    * VEL-101 IS EXPECTED TO IMPACT IMMUNE FUNCTION BOTH
DIRECTLY BY
BLOCKING CD28-MEDIATED T CELL ACTIVATION, INDIRECTLY THROUGH
PRESERVATION OF CTLA-4 MEDIATED IMMUNOREGULATORY FUNCTION

Source text for Eikon:  ID:nBw78k3dDa 
Further company coverage:  OSE.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48587696600;))